Desmopressin

DDAVP / Nocdurna / Stimate

Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of the natural antidiuretic hormone arginine vasopressin. Two deliberate modifications distinguish it from the parent hormone: removal of the amino group at position 1 and substitution of D-arginine for L-arginine at position 8. Together these changes make it resistant to enzymatic breakdown (extending its duration of action) and strongly selective for the vasopressin V2 receptor over the V1 receptor. The V2 selectivity is the whole point — it delivers the water-retaining, antidiuretic effect of vasopressin without the blood-vessel-constricting, blood-pressure-raising V1 effects. Clinically, desmopressin is one of the most established therapeutic peptides in medicine. By activating V2 receptors in the kidney's collecting ducts, it inserts aquaporin water channels that reabsorb water and concentrate the urine. This makes it the standard treatment for central (cranial) diabetes insipidus — where the body fails to make enough vasopressin — and for primary nocturnal enuresis (bedwetting) and nocturia (waking at night to urinate) in appropriately selected patients. A second, separate action underlies its use in bleeding: V2 stimulation triggers release of von Willebrand factor and factor VIII from vascular endothelium, which is why desmopressin is used to manage mild hemophilia A and type 1 von Willebrand disease. Desmopressin is available in multiple formulations — nasal spray, oral tablets, sublingual (melt) tablets, and injectable forms — chosen by indication and dose. Its defining safety concern is hyponatremia (dangerously low blood sodium) from water retention, which is why fluid intake is restricted around dosing, sodium is monitored, and the drug is used cautiously in older adults. It is a prescription medicine, not a research peptide, and dosing and formulation should be set by a clinician for the specific indication.